eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2020
vol. 37
 
Share:
Send email
Share:
abstract:
Original paper

The effect of levocetirizine and montelukast on clinical symptoms, serum level and skin expression of COX-1 and COX-2 enzymes in patients suffering from chronic autoimmune urticaria – a pilot study

Paulina Korczyńska-Krawczyk
1
,
Izabela Kupryś-Lipińska
1
,
Maciej Kupczyk
1
,
Małgorzata Wągrowska-Danilewicz
2
,
Janusz Szemraj
3
,
Wojciech Bienias
4
,
Joanna Narbutt
4
,
Janusz Śmigielski
5
,
Piotr Kuna
1

  1. Department of Internal Medicine, Asthma and Allergy, Norbert Barlicki Memorial University Hospital No. 1, Medical University of Lodz, Lodz, Poland
  2. Department of Nephropathology, Medical University of Lodz, Lodz, Poland
  3. Department of Medical Biochemistry, Faculty of Health Sciences with the Division of Nursing and Midwifery, Medical University of Lodz, Lodz, Poland
  4. Department of Dermatology and Pediatric and Oncologic Dermatology, Medical University of Lodz, Lodz, Poland
  5. Social and Technical Department, State Higher Vocational School, Konin, Poland
Adv Dermatol Allergol 2020; XXXVII (1): 73-80
DOI: https://doi.org/10.5114/ada.2018.79731
Online publish date: 2018/11/23
View full text Get citation
 
Introduction
Chronic autoimmune urticaria (CAU) lasts over 6 weeks and is characterized by circulating IgE autoantibodies or IgG against IgE or IgE receptor.

Aim
To assess the clinical, laboratory and histological effects of 4-week levocetirizine and montelukast therapy in patients suffering from CAU.

Material and methods
Of 296 tested patients with chronic urticaria 40 had a positive ASST test. Only 17 (16 female/1 male; medium age: 44 years) fulfilled all study inclusion/exclusion criteria. The study was designed as an open, randomized trial with two arms: levocetirizine or montelukast treatment for 4 weeks following a 2-week wash-out period. All participants completed urticaria activity score (UAS) and visual analogue scale (VAS) questionnaires before and after both therapies. Blood samples and skin bioptats were obtained before and after treatment to evaluate COX-1 and COX-2 serum concentrations and skin expression.

Results
Clinical response to therapy measured with the UAS and VAS was better in the levocetirizine group. Both drugs caused a significant decrease in COX-1 and COX-2 serum level. COX-1 and COX-2 expression in epidermal and dermal inflammatory infiltration did not change significantly in either study group, but a significant decrease of COX-1 expression was observed when the groups were combined for analysis, and the decrease in COX-2 expression in the epidermis was of borderline significance.

Conclusions
The effectiveness of levocetirizine and montelukast in treating CAU may be partly related to the reduction of COX-1 and COX-2 serum level and tissue expression, but further studies on a larger group of patients are needed to support this observation.

keywords:

chronic urticaria, cyclooxygenase, levocetirizine, montelukast
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.